Abstract
Carbapenems (CARBs) are the primary treatment for infections caused by extended-spectrum beta-lacta-mase (ESBL)-producing Klebsiella pneumoniae strains. Production of a serine carbapenemase, KPC, is increasing alarmingly in the United States and is probably contributing to CARB resistance rates. We describe the clinical and molecular characteristics of four infections caused by KPC-3 K. pneumoniae strains.
Original language | English |
---|---|
Pages (from-to) | 623-625 |
Number of pages | 3 |
Journal | Journal of Clinical Microbiology |
Volume | 48 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2010 |
ASJC Scopus subject areas
- Microbiology (medical)